Werfen USA LLC

Werfen USA LLC, a for-profit limited liability company based in Bedford, Massachusetts, supplies in vitro diagnostic equipment, clinical laboratory instrumentation, and associated reagents and consumables to federal healthcare agencies as a prime contractor, competing without small business set-asides in the full-and-open federal marketplace.

Werfen's federal footprint centers on coagulation analyzers, blood gas analyzers, hematology testing systems, blood bank analyzers, and specialized laboratory reagents—delivered to the Veterans Health Administration across multiple regional networks, the Defense Health Agency, Indian Health Service, and the National Institutes of Health Clinical Center. The company operates exclusively as a prime contractor with no subcontractor footprint; across its recent award history, 100 percent of awards are prime contracts, and SCI-reportable service-contract data show zero sub-engagement. Werfen manufactures and performs work from its Bedford facility and delivers products and services to customer sites nationwide, including specific VA medical centers across multiple Veterans Integrated Service Networks (VISNs) and Department of Defense military medical treatment facilities.

Customer concentration is extreme and Veterans Affairs-dominated. The top five funding agencies account for 45 percent of recent awards by count, but dollar concentration is far steeper: VISN 12 anchors $140.7 million (29 percent of Werfen's combined potential value) across 89 awards; VISN 15 carries $52 million across 40 awards; VISN 10 accounts for $31.6 million across 140 awards; VISN 1 represents $29.1 million across 115 awards; and VISN 17 totals $28.5 million across 86 awards. Together these five VISNs represent 58 percent of Werfen's combined potential value. The Defense Health Agency (97 awards, $17.4 million) and Indian Health Service (116 awards, $9.4 million) round out significant customer relationships, but the Veterans Health Administration is Werfen's dominant market—more than 80 percent of Werfen's federal work flows to VA VISNs across the network.

Werfen's business model is structured around two primary GSA Schedule vehicles. The Critical Analyzers, Laboratory schedule (FSS-66-III) carries 1,012 task orders valued at $190.5 million—roughly 40 percent of Werfen's federal portfolio—and is the dominant parent vehicle for coagulation testing, blood gas, and hematology equipment and consumables. The Multiple Award Schedule (MAS) holds 148 task orders worth $49 million, primarily for blood gas analyzers and equipment rental. The In Vitro Diagnostics, Reagents, Test schedule (FSS-65-VII) supports 145 task orders valued at $16.3 million for blood bank reagents and diagnostic supplies. Recent representative prime work includes a $671.955 million delivery order from VISN 15 in September 2026 for coagulation testing equipment and services on a cost-per-reportable-result basis; a $673.927 million delivery order from VISN 15 in July 2025 for coagulation analyzers and reagents; a $2.168 billion single-award BPA from the Department of Veterans Affairs in April 2026 for coagulation testing equipment and services across multiple VA facilities (ultimate completion March 2037); and a $1.374 billion single-award IDIQ from VISN 2 in November 2025 for blood gas testing instruments on a cost-per-test basis (ultimate completion October 2026). A $483 million purchase order from the Defense Health Agency in October 2025 covers blood bank analyzer leasing and reagents through September 2030.

Activity has remained consistent at 114–149 awards annually from 2022 through 2024, then accelerated to 199 awards in 2025 before moderating to 126 awards through October 2026. This year-to-date count reflects the most recent snapshot and does not yet represent a full fiscal or calendar year. A total of 157 awards carrying combined potential value of $29.9 million reach ultimate completion within the next twenty-four months, constituting meaningful recompete exposure across multiple VISN relationships.

NAICS and PSC coding confirms the portfolio's diagnostic-device focus: 1,024 awards (69 percent) fall under Analytical Laboratory Instrument Manufacturing (NAICS 334516); 275 awards (18 percent) fall under In-Vitro Diagnostic Substance Manufacturing (NAICS 325413). Product service code 6632 (Laboratory Equipment and Supplies) governs 602 awards; PSC 6635 (In Vitro Diagnostic Substances, Reagents, Test Kits and Sets) covers 416 awards. Werfen maintains no recorded subcontract footprint and performs all work as a prime contractor, building its own delivery capability in-house rather than leveraging sub relationships.

Service Contract Inventory activity is minimal and does not reflect Werfen's true federal revenue scale. SCI records only service contracts above $150,000 and excludes goods and products—precisely the commodities that dominate Werfen's federal business (laboratory analyzers, reagents, consumables). The SCI dataset shows only $16 thousand in invoiced revenue across FY2022 and FY2024, with zero FTE movement, because Werfen's federal work is predominantly transactional product delivery and equipment leasing rather than labor-hour-based services. This figure is not representative of Werfen's actual federal revenue, which the combined potential value across all awards ($486 million) and obligated dollars ($128.4 million) suggest operates at a far larger scale.

Werfen competes in the federal marketplace without small business set-aside eligibility and has not been awarded federal contracts using set-aside vehicles. The vendor holds no IDIQ positions on GWACs or governmentwide vehicles outside the GSA Schedule ecosystem; its contracting relationship is built almost entirely through GSA Schedule task orders and single-award BPAs issued directly by VA VISNs and other customer agencies. This positioning makes Werfen a pure GSA Schedule player and a direct competitor to other full-sized diagnostic equipment manufacturers seeking VA and Defense Health Agency work.